quest diagnostics false positive drug tests

Quest Diagnostics Introduces Confirmatory Testing Service for Novel Psychoactive Substances

The detection of drug misuse in patients prescribed controlled medications has become a pressing concern in the healthcare community, particularly with the proliferation of synthetic or 'designer' drugs in the nation's drug supply. Quest Diagnostics, a leading provider of diagnostic information services, has recently unveiled its new confirmatory testing service for novel psychoactive substances (NPS) to help healthcare providers address this issue.

The NPS are versions of established prescription and illicit drugs that have been chemically altered to enhance their effects and evade tracking by law enforcement. These substances are often marketed as legal alternatives to illegal drugs, but they can be just as dangerous and addictive. The new test panel designed by Quest Diagnostics is intended to help healthcare providers detect potential drug misuse in patients prescribed controlled medications, such as opioids and other substances.

The new panel tests for 88 compounds, covering a broad array of drug classes, including designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additives. Two of these classes are rapidly accelerating America's overdose crisis: other illicit additives (xylazine) and fentanyl analogs (acetyl fentanyl). The presence of these substances in a patient's system can have severe consequences, including respiratory depression, coma, and even death.

Quest Diagnostics' new confirmatory testing service for NPS is designed to provide healthcare providers with accurate and reliable results, enabling them to make informed decisions about treatment and patient care. By detecting the use of these dangerous substances, healthcare providers can take proactive steps to prevent addiction and overdose, ultimately saving lives.

In conclusion, Quest Diagnostics' introduction of a confirmatory testing service for novel psychoactive substances is a significant step forward in addressing the growing problem of drug misuse and overdose in America. As the nation grapples with an opioid epidemic, it is more important than ever that healthcare providers have access to accurate and reliable testing methods to identify and address drug use.

Quest diagnostics false positive drug tests